Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P35610
UPID:
SOAT1_HUMAN
Alternative names:
Acyl-coenzyme A:cholesterol acyltransferase 1; Cholesterol acyltransferase 1
Alternative UPACC:
P35610; A6NC40; A8K3P4; A9Z1V7; B4DU95; Q5T0X4; Q8N1E4
Background:
Sterol O-acyltransferase 1, also known as Acyl-coenzyme A:cholesterol acyltransferase 1 and Cholesterol acyltransferase 1, plays a pivotal role in lipid metabolism. It catalyzes the formation of fatty acid-cholesterol esters, crucial for maintaining membrane fluidity and facilitating lipoprotein assembly. This enzyme exhibits a preference for oleoyl-CoA as a substrate, highlighting its specificity in lipid processing.
Therapeutic significance:
Understanding the role of Sterol O-acyltransferase 1 could open doors to potential therapeutic strategies. Its involvement in cholesterol absorption and lipoprotein assembly positions it as a key target for addressing dyslipidemia and atherosclerosis, offering a pathway to novel treatments.